363 related articles for article (PubMed ID: 32375062)
1. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Jian C; Fu J; Cheng X; Shen LJ; Ji YX; Wang X; Pan S; Tian H; Tian S; Liao R; Song K; Wang HP; Zhang X; Wang Y; Huang Z; She ZG; Zhang XJ; Zhu L; Li H
Cell Metab; 2020 May; 31(5):892-908.e11. PubMed ID: 32375062
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.
Sun X; Seidman JS; Zhao P; Troutman TD; Spann NJ; Que X; Zhou F; Liao Z; Pasillas M; Yang X; Magida JA; Kisseleva T; Brenner DA; Downes M; Evans RM; Saltiel AR; Tsimikas S; Glass CK; Witztum JL
Cell Metab; 2020 Jan; 31(1):189-206.e8. PubMed ID: 31761566
[TBL] [Abstract][Full Text] [Related]
4. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib.
Bai J; Liu Z; Liu J; Zhang S; Tian Y; Zhang Y; Ren L; Kong D
Aging (Albany NY); 2019 Dec; 11(24):12452-12475. PubMed ID: 31881007
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
7. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
[TBL] [Abstract][Full Text] [Related]
8. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells.
Rodríguez-Hernández MA; de la Cruz-Ojeda P; Gallego P; Navarro-Villarán E; Staňková P; Del Campo JA; Kučera O; Elkalaf M; Maseko TE; Červinková Z; Muntané J
Biochem Pharmacol; 2020 Jun; 176():113902. PubMed ID: 32156660
[TBL] [Abstract][Full Text] [Related]
10. Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma.
Suk FM; Wang YH; Chiu WC; Liu CF; Wu CY; Chen TL; Liao YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445279
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
[TBL] [Abstract][Full Text] [Related]
12. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
13. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Xu W; Gong W; Shao L
Gene; 2020 Aug; 753():144807. PubMed ID: 32461017
[TBL] [Abstract][Full Text] [Related]
14. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1.
Garten A; Grohmann T; Kluckova K; Lavery GG; Kiess W; Penke M
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31430957
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
[TBL] [Abstract][Full Text] [Related]
17. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
[TBL] [Abstract][Full Text] [Related]
18. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
20. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
